CLINICAL_TRIALS
trial_result
· 2017-04-04
Clinical Trial Update: Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer [Phase 2]
Summary
Phase 2 trial update evaluating systemic and topical treatments to manage rash caused by erlotinib in non-small cell lung cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: British Columbia Cancer Agency | Conditions: Rash | Phase 2 | Status: COMPLETED | Results posted: 2017-04-04